Latest news with #Penumbra
Yahoo
a day ago
- Business
- Yahoo
Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
ALAMEDA, Calif., June 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii. "We've engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings," said Shruthi Narayan, President of Interventional Business at Penumbra, Inc. "Ruby XL embodies Penumbra's commitment to innovation, delivering mechanical occlusion through more volume without sacrificing softness or deliverability." The Ruby XL System introduces three unique technologies — Ruby XL, POD® XL, and Packing Coil XL — all of which can be delivered through a 0.035"+ diagnostic catheter. They have a primary diameter of .030" and are designed for procedural efficiency. These coils offer more volume (up to 40mm in size) and are available in extended lengths up to 70 cm. Engineered with a 3D complex shape, Ruby XL coil is designed to frame aneurysms in a variety of clinical applications. POD XL features a hybrid, multistage design and is engineered with three-in-one coil occlusion technology — an anchoring segment, a framing segment, and a dense filling segment. Designed for high flow vessels, POD XL offers smooth delivery and targeted vessel control. Packing Coil XL features an innovative liquid metal wave shape technology, which is designed to adjust dynamically to the size of any vessel (up to 70 cm length). Penumbra's Ruby portfolio of peripheral embolization products, now with Ruby XL System, provides physicians with one of the most expansive embolization offerings, enabling physicians to have the latest coil technologies and most extensive options for every case. For more information, please visit About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT™), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit and connect on Instagram, LinkedIn and X. Important Safety InformationAdditional information about Penumbra's products can be located on Penumbra's website at Caution: Federal (USA) law restrictions these devices to sale by or on the order of a physician. Prior to use, please refer to the Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events, and detailed instructions for use. Please visit for the complete IFU Summary Statements. The clinical results presented herein are for informational purposes only, and may not be predictive for all patients. Individual results may vary depending on patient-specific attributes and other factors. Forward-Looking Statements Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. ContactJennifer Heth Parinaz Farzin Penumbra, Inc. Merryman Communications jheth@ parinaz@ 510-995-9791 310.600.6746______________________ i Data as of May 2025, Ruby XL System is the largest and longest detachable embolization coil commercially available and the only 035 packing coil commercially available. ii Ruby XL is 2X larger than Ruby 020 coils and 3X larger than conventional 035 coils. Fewer coils used may potentially lead to reduced radiation exposure. View original content to download multimedia: SOURCE Penumbra, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
3 Reasons to Sell PEN and 1 Stock to Buy Instead
Penumbra currently trades at $256.16 per share and has shown little upside over the past six months, posting a middling return of 4.5%. However, the stock is beating the S&P 500's 1.9% decline during that period. Is now the time to buy Penumbra, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free. Even with the strong relative performance, we don't have much confidence in Penumbra. Here are three reasons why we avoid PEN and a stock we'd rather own. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $1.24 billion in revenue over the past 12 months, Penumbra is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. Penumbra has shown mediocre cash profitability over the last five years, giving the company limited opportunities to return capital to shareholders. Its free cash flow margin averaged 3%, subpar for a healthcare business. Growth gives us insight into a company's long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). Penumbra's five-year average ROIC was negative 1.4%, meaning management lost money while trying to expand the business. Investors are likely hoping for a change soon. Penumbra isn't a terrible business, but it isn't one of our picks. Following its recent outperformance in a weaker market environment, the stock trades at 64× forward P/E (or $256.16 per share). At this valuation, there's a lot of good news priced in - we think there are better investment opportunities out there. Let us point you toward the Amazon and PayPal of Latin America. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Daily Record
30-05-2025
- Health
- Daily Record
Healthy 'n' Happy to host community event in Rutherglen
The June 13 workshop is part of the charity's 'Creating Hope in our Community' initiative A busy local charity is hosting a special event as part of its 'Creating Hope in our Community' campaign, dedicated to positive mental health and suicide prevention across Cambuslang and Rutherglen. Healthy 'n' Happy Community Development Trust is inviting residents and community representatives to the June 13 workshop with expert Louise McSharry of Penumbra's self-harm network, who will lead a session on supporting people who have issues with self-harm. It follows the success of the organisation's previous campaign event in November, when they arranged a special showing of 'moving and uplifting' film The Low Road, joined by director Stephen Mulhearn and producer Sophie Marsh. The latest event takes place at the Number 18 venue on Rutherglen's Farmeloan Road on Friday, June 13, from 10am to 1pm, when visiting guest Louise will run an informative workshop and host a question-and-answer session. Healthy 'n' Happy executive lead Mark Soanes said: 'We'd strongly encourage Cambuslang and Rutherglen residents, community groups, charities, statutory services and businesses to come along, so we can all work collaboratively to improve mental health in our community and provide vital support. 'You can all be part of this much-needed and important movement, to make a huge difference to you and the lives of those around you. 'Louise is very well versed on many topics surrounding mental health and has an amazing insight into this important will also have updates on useful upcoming training and will discuss best practice for promoting good mental wellbeing.'
Yahoo
22-05-2025
- Business
- Yahoo
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
Penumbra's PEN shares have registered impressive momentum in the past year, with shares rallying 35.9%. It has outperformed the industry's 13.3% decline. However, the S&P 500 composite has gained 11.6% during the same period. Carrying a Zacks Rank #3 (Hold) at present, the renowned thrombectomy company benefits from the strong customer uptake of its Lightning Bolt and Flash lines in both the U.S. and international markets. Penumbra's overseas operations show strong potential for growth and profit improvement. Solid financial health also bodes well for the stock. Alameda, CA-based Penumbra develops innovative technologies for challenging medical conditions such as ischemic stroke; venous thromboembolism, such as pulmonary embolism; and acute limb ischemia. The company has a solid track record of organic product development and commercial expansion, serving as the basis of its global organization. Penumbra sells products to healthcare providers mainly through its direct sales organization in the United States, most of Europe, Canada and Australia, as well as through distributors in select international markets. The rally in the share price can be linked to the company's consistent revenue growth momentum, led by the extraordinary patient outcomes from treatment using Lightning Flash, Lightning Bolt 7 and RED 72 with SENDit technology. Penumbra is seeing an acceleration of Lightning Bolt 7 cases in the past few months as conversion from surgery, lytics and other mechanical thrombectomy products is gaining momentum. Robust adoption of Flash 2.0 in VTE (Pulmonary Embolism and Deep Vein Thrombosis) is driven by its speed, safety and efficacy. Meanwhile, Lightning Bolt 7 and the newly launched Bolt 6X and Bolt 12 are accelerating conversion from surgery, lytics and other devices in arterial cases. Image Source: Zacks Investment Research Penumbra's core U.S. thrombectomy business continues to gain traction, delivering 25% year-over-year growth in the first quarter of 2025. This was driven by continued adoption and further market penetration of the current Computer Assisted Vacuum Thrombectomy (CAVT) portfolio, Lightning Flash 2.0 and Lightning Bolt 7. The U.S. VTE franchise was a standout, gaining 42% year over year. The recent launch of the RED 72 (SILVER LABEL) catheter has been met with enthusiastic clinical uptake, reinforcing Penumbra's leadership in stroke care. In the first quarter, Penumbra's international thrombectomy revenues grew 18.2% year over year, driven by solid momentum in regions outside China, particularly in EMEA. The company expects to meaningfully grow both international revenue and profitability in the next few years. Penumbra has already expanded CAVT's footprint into Europe and additional regions outside the United States, and has taken steps to optimize its geographic presence. Additionally, investors are upbeatabout the company's consistently stable solvency position. Penumbra exited the 2025 first quarter with cash and cash equivalents of $379 million, up from $340 million at the end of the fourth quarter of 2024. Total debt stood at $21 million, well below its cash reserves, with no short-term debt payable reported. Like other industry players, Penumbra's business is currently impacted by worldwide geopolitical complications, leading to widespread impact on global supply chains and labor markets. These have resulted in cost escalation and raw material supply constraints, as well as an increase in employee turnover rates in certain jurisdictions. The Zacks Consensus Estimate for Penumbra's 2025 and 2026 earnings per share (EPS) is expected to increase 69.8% and 35.3%, respectively, to $3.77 and $5.11. In the past 30 days, the Zacks Consensus Estimate for the company's 2025 EPS has increased by 3.6%. Revenues for 2025 are projected to grow 13.4% to $1.35 billion, followed by a 14.2% increase to $1.55 billion in 2026. Some better-ranked stocks in the broader medical space are Phibro Animal Health PAHC, Prestige Consumer Healthcare PBH and Inspire Medical Systems INSP. Phibro Animal Health has an estimated long-term earnings growth rate of 26.2% compared with the industry's 15.9% rise. Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry's 10% growth in the past year. PAHC carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Prestige Consumer Healthcare, currently carrying a Zacks Rank #2, has an earnings yield of 5.4% compared with the industry's flat yield. Shares of the company have rallied 30.3% compared with the industry's 10% growth. PBH's earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. Inspire Medical Systems, carrying a Zacks Rank #2 at present, has an estimated long-term earnings growth rate of 28.9% compared with the industry's 25.2%. Shares of the company have fallen 9.5% against the industry's 19.6% growth. INSP's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 356.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Prestige Consumer Healthcare Inc. (PBH) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 6.4%. This performance was disappointing since the S&P 500 held its ground. A cautious approach is imperative when dabbling in these businesses as regulation is another unpredictable element that can affect their earnings potential. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $10.87 billion Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions. Why Does PEN Fall Short? Modest revenue base of $1.24 billion gives it less fixed cost leverage and fewer distribution channels than larger companies Low free cash flow margin of 3% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders Negative returns on capital show that some of its growth strategies have backfired Penumbra is trading at $281.56 per share, or 70.3x forward P/E. Check out our free in-depth research report to learn more about why PEN doesn't pass our bar. Market Cap: $3.33 billion With roots dating back to 1877 when it introduced the first dental electric drill, Dentsply Sirona (NASDAQ:XRAY) manufactures and sells professional dental equipment, technologies, and consumable products used by dentists and specialists worldwide. Why Do We Think XRAY Will Underperform? Weak constant currency growth over the past two years indicates challenges in maintaining its market share Sales were less profitable over the last five years as its earnings per share fell by 7% annually, worse than its revenue declines Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Dentsply Sirona's stock price of $16.72 implies a valuation ratio of 8.8x forward P/E. Dive into our free research report to see why there are better opportunities than XRAY. Market Cap: $868.7 million With a network of thousands of healthcare professionals ranging from nurses to physicians to executives, AMN Healthcare (NYSE:AMN) provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms for hospitals and healthcare facilities across the United States. Why Do We Pass on AMN? Declining travelers on assignment over the past two years indicate demand is soft and that the company may need to revise its strategy Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $22.17 per share, AMN Healthcare Services trades at 18.5x forward P/E. If you're considering AMN for your portfolio, see our FREE research report to learn more. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.
